Cancer Plasticity: Mechanisms, Resistance, and Targets

Peter Novak
Department of Oncology and Molecular Medicine, Charles University, Prague, Czech Republic

*Corresponding Authors**

Peter Novak
Department of Oncology and Molecular Medicine, Charles University, Prague, Czech Republic
E-mail: peter.novak@cuni.cz

Received: 01-Jul-2025; **Accepted:** 08-Aug-2025; **Published:** 08-Aug-2025

Introduction

Cancer cells are incredibly adaptable, a trait called plasticity, allowing them to shift identities and evade treatments. This review discusses the mechanisms driving this plasticity, such as epigenetic changes and interactions within the tumor microenvironment, and explores therapeutic strategies aiming to target these adaptable states to prevent drug resistance and improve patient outcomes [1].

This paper delves into how colorectal cancer cells exhibit cellular plasticity and undergo clonal evolution, processes fundamental to tumor initiation, progression, and therapeutic resistance. It highlights the dynamic interplay of genetic and epigenetic alterations that drive these changes, suggesting that understanding these mechanisms is key to developing more effective and targeted therapies for colorectal cancer patients [2].

The article explores the intricate relationship between cancer cell metabolism and the efficacy of immunotherapy. It details how tumor cells reprogram their metabolism to support rapid growth and suppress anti-tumor immune responses, and discusses strategies to target these metabolic pathways to enhance the effectiveness of immune checkpoint inhibitors and other immunotherapies [3].

Ferroptosis, a regulated form of cell death characterized by iron-dependent lipid peroxidation, is gaining traction as a potential anti-cancer therapy. This review outlines the molecular mechanisms driving ferroptosis, identifies strategies to induce it in resistant cancer cells, and addresses the challenges in translating these findings into effective clinical treatments, positioning ferroptosis as a promising avenue in cancer research [4].

This comprehensive review details the significant impact of Immune Checkpoint Inhibitors (ICIs) on cancer therapy. It covers the underlying biological principles, clinical applications across various cancer types, mechanisms of resistance, and ongoing research into combination therapies and biomarkers to predict response, highlighting ICIs as a cornerstone of modern oncology [5].

The Tumor Microenvironment (TME) is much more than just a support system for cancer cells; it actively dictates tumor growth, metastasis, and response to therapy. This article dissects the complex cellular and non-cellular components of the TME, including immune cells, fibroblasts, and extracellular matrix, and discusses how targeting these elements can enhance the efficacy of existing and emerging cancer treatments [6].

This review highlights the transformative impact of single-cell technologies in unraveling the heterogeneity of cancer and its microenvironment. It showcases how these techniques provide unprecedented insights into tumor evolution, drug resistance mechanisms, and the identification of novel therapeutic targets, paving the way for more personalized and effective cancer treatments [7].

This article focuses on the critical role of epigenetic modifications in driving cancer development and progression. It discusses various epigenetic mechanisms, such as DNA methylation and histone modifications, as key therapeutic targets. The review also explores the current landscape of epigenetic drugs and strategies to develop more potent and selective agents for cancer treatment [8].

Chronic inflammation is a known hallmark of cancer, significantly contributing to tumor initiation, progression, and metastasis. This review elucidates the complex interplay between inflammatory mediators, immune cells, and cancer cells, highlighting how persistent inflammation creates a pro-tumorigenic microenvironment and discussing therapeutic strategies aimed at disrupting these inflammatory pathways to inhibit cancer spread [9].

Autophagy, a cellular recycling process, exhibits a dual role in cancer, acting as both a tumor suppressor and a promoter depending on the context and stage of the disease. This article explores the intricate mechanisms of autophagy regulation in cancer cells, its implications for therapeutic resistance, and the potential for targeting autophagy to either inhibit tumor growth or enhance the effectiveness of other cancer treatments [10].

Description

Cancer's ability to evolve and resist treatment is a central challenge in oncology. A key aspect of this challenge is cellular plasticity, where cancer cells can alter their identity to evade therapies. This adaptability is influenced by epigenetic changes and the dynamic interactions within the Tumor Microenvironment (TME) [1, 2]. Understanding how these mechanisms drive plasticity is crucial for developing targeted interventions, particularly in complex diseases like colorectal cancer, where genetic and epigenetic alterations underpin tumor initiation and progression [2]. Strategies that aim

Cite this article: Novak P,(2025) Cancer Plasticity: Mechanisms, Resistance, and *Targets. jmcb* 07: 159. DOI: 1037532.jmcb.2025.7.2.159

to target these adaptable cancer states promise to prevent drug resistance and improve outcomes for patients [1].

The Tumor Microenvironment (TME) itself is a critical determinant of cancer behavior, extending far beyond a mere support system [6]. It actively orchestrates tumor growth, metastasis, and response to therapeutic agents. The TME comprises a complex array of cellular components, including various immune cells and fibroblasts, alongside non-cellular elements like the extracellular matrix. Dissecting these intricate components reveals how targeting specific elements within the TME can significantly enhance the effectiveness of both existing and novel cancer treatments [6]. Moreover, chronic inflammation is a recognized hallmark of cancer, playing a substantial role in tumor initiation, progression, and metastasis [9]. The persistent interplay between inflammatory mediators, immune cells, and cancer cells creates a pro-tumorigenic microenvironment. Disrupting these inflammatory pathways represents a vital therapeutic strategy to inhibit cancer spread and improve patient prognosis [9].

Cancer cells also exhibit significant metabolic reprogramming to fuel their rapid growth and simultaneously suppress anti-tumor immune responses [3]. This metabolic shift presents a promising therapeutic vulnerability. Strategies focused on targeting these altered metabolic pathways have the potential to boost the efficacy of immunotherapies, including Immune Checkpoint Inhibitors (ICIs) [3]. ICIs have profoundly impacted cancer therapy, establishing themselves as a cornerstone of modern oncology [5]. Comprehensive reviews explore their biological underpinnings, widespread clinical applications across diverse cancer types, mechanisms of resistance, and the ongoing research into combination therapies and predictive biomarkers to maximize their therapeutic benefits [5].

Beyond these established and emerging therapeutic modalities, novel approaches like ferroptosis are gaining prominence. Ferroptosis is a regulated form of cell death characterized by iron-dependent lipid peroxidation, offering a distinct pathway for anti-cancer intervention [4]. Research is focused on elucidating its molecular mechanisms, identifying ways to induce it specifically in resistant cancer cells, and addressing the translational hurdles to bring these findings to clinical practice [4]. Furthermore, epigenetic modifications, such as DNA methylation and histone modifications, are recognized as critical drivers of cancer development and progression [8]. These modifications represent significant therapeutic targets, with ongoing efforts to develop more potent and selective epigenetic drugs for cancer treatment [8].

Finally, the field benefits immensely from technological advancements. Single-cell technologies, for instance, are revolutionizing cancer research by providing unprecedented insights into tumor heterogeneity and the microenvironment [7]. These techniques are instrumental in unraveling tumor evolution, mechanisms of drug resistance, and identifying novel therapeutic targets. This high-resolution understanding paves the way for increasingly personalized and effective cancer treatments [7]. Autophagy, a fundamental cellular recycling process, also holds a complex, dual role in cancer, acting as either a suppressor or promoter depending on the context [10]. Exploring the intricate regulation of autophagy in cancer cells, its implications for therapeutic resistance, and its potential as a targeted intervention, either to inhibit tumor growth or enhance other treatments, remains a significant area of investigation [10].

Conclusion

Cancer research actively explores the multifaceted nature of tumor progression and therapy resistance. A central theme is the remarkable plasticity of cancer cells, which allows them to change identities and evade treatments. This adaptability is driven by factors like epigenetic changes and interactions within the Tumor Microenvironment (TME). Understanding these mechanisms is key to developing strategies to prevent drug resistance and improve patient outcomes, particularly in cancers like colorectal cancer. The TME itself plays a crucial role, influencing growth, metastasis, and treatment response through its complex cellular and non-cellular components. Targeting these elements can significantly enhance existing and emerging therapies.

Metabolic reprogramming in tumor cells supports rapid growth and suppresses anti-tumor immune responses, making metabolic pathways a prime target for improving immunotherapy efficacy. Immunotherapy, especially using Immune Checkpoint Inhibitors (ICIs), has transformed cancer treatment. Research focuses on their biological principles, clinical applications, resistance mechanisms, and combination therapies, cementing ICIs as a cornerstone of modern oncology.

Beyond traditional therapies, novel approaches are gaining traction. Ferroptosis, a regulated form of cell death, shows promise as an anti-cancer strategy, with ongoing efforts to induce it in resistant cells. Epigenetic modifications are vital drivers of cancer, offering targets for new drugs. Chronic inflammation also significantly contributes to tumor initiation and spread, making inflammatory pathways a therapeutic target. Autophagy, a cellular recycling process, has a complex dual role in cancer, with potential for targeted modulation to inhibit growth or enhance treatments. Advanced single-cell technologies are revolutionizing the field, providing unprecedented insights into tumor heterogeneity, evolution, and drug resistance, thereby paving the way for personalized and more effective cancer treatments. This collective understanding points towards a future of more nuanced and targeted cancer interventions.

References

1. Christian R, Michael HR, *Andrea SW. Targeting cancer cell plasticity to overcome therapeutic resistance. Nat Rev Clin Oncol.* 2024;21:321-341.
2. Olivier G, Wouter VH, *Charlotte B. Cellular Plasticity and Clonal Evolution in Colorectal Cancer. Cancers* (Basel). 2024;16:965.
3. Wenxuan H, Yuhong M, *Fan W. Metabolic Reprogramming and Cancer Immunotherapy. Cell Metab.* 2024;36:11-28.
4. Guangxiao L, Xinmin W, Jiao Z. Targeting ferroptosis in cancer: mechanisms, therapeutic strategies, and challenges. *Cell Death Differ.* 2022;29:2223-2244.
5. Padmanee S, Robert JV, Jason L. Immune checkpoint inhibitors in cancer therapy: a comprehensive review. *Cancer Cell.* 2021;39:894-911.
6. Borislav A, Ann-Sophie K, Franziska M. The tumor microenvironment: a crucial determinant of cancer progression and therapeutic response. *J Clin Med.* 2020;9:3009.
7. Haochen Y, Siyuan C, Lingtao Z. Single-cell technologies in cancer research: from mechanisms to new therapies. *Nat Rev Clin Oncol.* 2023;20:655-675.

Cite this article: Novak P,(2025) Cancer Plasticity: Mechanisms, Resistance, and *Targets. jmcb* 07: 159. DOI: 1037532.jmcb.2025.7.2.159

8. Mark AD, John ED, Stephen TL. Epigenetic regulation in cancer: mechanisms, targets, and therapeutic strategies. *Cell.* 2020;182:816-831.

9. Francesco C, Alessandra A, *Clara S. The role of inflammation in cancer progression and metastasis. Cancers* (Basel). 2020;12:2415.

10. Xuping M, Yongjie W, Qi L. Autophagy in cancer: a double-edged sword. *Cancers* (Basel). 2020;12:3396.

Cite this article: Novak P,(2025) Cancer Plasticity: Mechanisms, Resistance, and *Targets. jmcb* 07: 159. DOI: 1037532.jmcb.2025.7.2.159